Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate

Vandana Singh
1 min read
0
In this article:

  • Provention Bio Inc (NASDAQ: PRVB) has entered into a co-promotion agreement with Sanofi SA (NASDAQ: SNY) to launch Provention's lead investigational candidate, teplizumab, to delay type 1 diabetes in at-risk individuals.

  • Teplizumab is under FDA review, with an action date of November 17.

  • Under the terms of the agreement, Sanofi will commit commercial resources in the U.S. In exchange, Provention will reimburse field force-related expenses that Sanofi will incur in connection with commercializing teplizumab under the agreement.

  • Also read: Provention Bio's Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months.

  • Provention retains all rights to teplizumab and maintains responsibility for the commercialization strategy.

  • The company also granted Sanofi, in consideration of a one-time payment of $20 million, an exclusive, one-time right of first negotiation (ROFN) to obtain exclusive global rights to commercialize teplizumab for Type 1 diabetes.

  • Sanofi may exercise the ROFN, until June 30, 2023, with an option to extend within 2023 under certain conditions.

  • Simultaneously, Sanofi has agreed to purchase $35 million of Provention Bio's stock.

  • Price Action: PRVB shares are up 13.1% at $5.60 during the premarket session on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories